Compare AIDX & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIDX | CMND |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 3.2M |
| IPO Year | 2025 | 2021 |
| Metric | AIDX | CMND |
|---|---|---|
| Price | $0.18 | $3.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 206.0K | 5.2K |
| Earning Date | 11-16-2026 | 09-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.48 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,045,133.00 | N/A |
| Revenue This Year | $44.20 | N/A |
| Revenue Next Year | $95.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.71 | N/A |
| 52 Week Low | $0.18 | $0.07 |
| 52 Week High | $18.96 | $7.16 |
| Indicator | AIDX | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 30.30 | 24.30 |
| Support Level | N/A | $0.58 |
| Resistance Level | $0.27 | $4.66 |
| Average True Range (ATR) | 0.03 | 0.43 |
| MACD | 0.00 | -0.41 |
| Stochastic Oscillator | 0.00 | 0.32 |
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.